Risk Assessment of Physiological Effects of Atmospheric Composition and Pressure in Constellation Vehicles by Scheuring, Richard A. et al.
Risk Assessment of Physiological  Effects of Atmospheric Composition and Pressure 
in Constellation Vehicles 
 
Conkin J1, Jones JA2, Scheuring RA3 , Mike Gernhardt2 Universities Space Research 
Association1, NASA / Johnson Space Center / SD/SK2, Wyle Laboratories, Life 
Sciences, Systems, and Services 3  Houston, Texas, USA 77058. 
 
Introduction: To limit the risk of fire and reduce denitrogenation time to prevent 
decompression sickness to support frequent extravehicular activities on the Moon, a 
hypobaric (PB = 414 mmHg) and mildly hypoxic (ppO2 = 132 mmHg, 32% O2 - 68% 
N2) living environment is considered for the Crew Exploration Vehicle (CEV) and Lunar 
Surface Access Module (LSAM).  With acute change in ppO2 from 145-178 mmHg at 
standard vehicular operating pressure to  less than 125 mmHg at desired lunar surface 
vehicular operating pressures, there is the possibility that some crewmembers may 
develop symptoms of Acute Mountain Sickness (AMS). The signs and symptoms of 
AMS (headache plus nausea, dizziness, fatigue, or sleeplessness), could impact crew 
health and performance on lunar surface missions. Methods:  An exhaustive literature 
review on the topic of the physiological effects of reduced ppO2 and absolute pressure as 
may contribute to the development of altitude symptoms or AMS. The results of the nine 
most rigorous studies were collated, analyzed and contents on AMS and hypoxia 
symptoms summarized. Results:  There is evidence for an absolute pressure effect per se 
on AMS, so the higher the altitude for a given hypoxic alveolar O2 partial pressure 
(PAO2), the greater the AMS response.  About 25% of adults are likely to experience 
mild AMS near 2,000 m altitude following a rapid ascent from sea level while breathing 
air (6,500 feet, acute PAO2 = 75 mmHg).  The operational experience with the Shuttle 
staged denitrogenation protocol at 528 mmHg (3,048 m) while breathing 26.5% O2 
(acute PAO2 = 85 mmHg) in astronauts adapting to microgravity suggests a similar likely 
experience in the proposed CEV environment.  Conclusions:  We believe the risk of mild 
AMS is greater given a PAO2 of 77 mmHg at 4,876 m altitude while breathing 32% O2 
than at 1,828 m altitude while breathing 21% O2.  Only susceptible astronauts would 
develop mild and transient AMS with prolonged exposure to 414 mmHg (4,876 m) while 
breathing 32% O2 (acute PAO2 = 77 mmHg).  So the following may be employed for 
operational risk reduction:  1) develop procedures to increase PB as needed in the CEV, 
and use a gradual or staged reduction in cabin pressure during lunar outbound; 2) train 
crews for symptoms of hypoxia, to allow early recognition and consider pre-adaptation of 
crews to a hypoxic environment prior to launch, 3) consider prophylactic acetazolamide 
for acute pressure changes and be prepared to treat any AMS associated symptoms early 
with both carbonic anhydrase inhibitors and supplemental oxygen. 
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3Background
♦ Atmosphere Design Considerations:
• Limit Hypoxia.
• Reduce Risk of Fire
• Prevent Decompression Sickness (DCS) and Venous Gas Emboli (VGE).
• Optimization of atmosphere(s) design to allow safe and efficient EVAs.
♦ Risks addressed:
• Mitigate risk of significant hypoxia.
• Mitigate / eliminate risk of serious DCS and VGE during EVA.
⎯ Better to prevent rather than treat DCS, or to constantly embolize the lung.
♦ Underlying Assumptions:
• Efficient and frequent EVAs drive the exploration initiative.
• Low pressure suit is always preferred to high pressure suit. 
• There is an operational value to a short in-suit prebreathe. 
• Vehicle atmosphere may not prevent risk of DCS during EVA.
⎯ Shuttle and ISS atmospheres are examples.
• Dedicated hyperbaric treatment capability may not be present.
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Mask and in-suit; 
staged w/exercise
29.6 (4.3)21101.3 (14.7)ISS/US
In-suit29.6 (4.3)21101.3 (14.7)
-25.8 (3.75)7034.5 (5)Skylab
-25.8 (3.75)10034.5 (5)Gemini/Apollo
--10034.5 (5)Mercury
EVA Prebreathe 
Conditions
EVA Suit 
Pressure,(1)
kPa (psia)
Cabin Oxygen 
Concentration,
volume %
Cabin 
Pressure,
kPa (psia)
Program
Historical Spacecraft Atmospheres
(From Lange, et al, 2005)
5Environment
PB
psia mmHg
FIO2
(%)
PIO2
mmHg
PAO2
mmHg
Actual Altitude
m         feet
Equivalent Air 
Altitude
m         feet
CEV + LSAM
normal 8.0     414 32.0 117 77 4,877   16,000 1,829   6,000
best case 8.2     424 34.0 128 86 4,816   15,800 1,158   3,800
worse case 7.8     403 30.0 107 68 5,029   16,500 2,438   8,000
HABITAT
normal 7.6     393 32.0 111 71 5,182   17,000 2,286   7,500
best case 7.8     403 34.0 121 80 5,029  16,500 1,524   5,000
worse case 7.4     383 30.0 101 63 5,364  17,600 2,895   9,500
PIO2 is inspired O2 partial pressure, computed as (PB mmHg – 47) * FIO2 (as decimal fraction).
PAO2 is computed acute alveolar oxygen partial pressure from alveolar oxygen equation.
Future Spacecraft Atmospheres
6Note 1:  Range of total pressure capability covers Earth launch, Earth entry, and contingencies.    
Note 2:  Surface suit 3.5 psia capability for suit emergency operations, 8.0 psia for DCS treatment.
Note 3: 60 minute in-suit prebreathe is defined as the time in the suit after purge and leak check until  
absolute pressure on the body reaches 4.3 psia after a nominal depressurization.  Nitrogen is assumed diluent gas.
Note 4:  All nominal values are centers of control boxes assumed +/-0.2 psia total pressure, +/-2% oxygen.
Note 5:  10.2 psia recommendation is based on Shuttle experience, for CEV contingency EVA preparation. 6
Summary of Recommendations for Constellation Mission Systems
Vehicle
Nominal
Total Pressure
( psia 
+/- 0.2 psia ) 4
Nominal Oxygen 
Partial Pressure 
(mmHg) 4
Nominal Oxygen
Concentration 
( %
+/- 2.0 % )4
Range of Total 
Pressure Capability
(psia) 1
Tissue Ratio ( R ) 
After 60 Minutes
Prebreathing3
CEV to ISS 14.710.25
160 ( 0 ft )
140 (3500 ft)
21
26.5 0-14.9
CEV In-Space Suit 4.3 222 100 4.0-4.6
1.55 from 10.2 psia 
CEV to 4.3 psia 
suit
Lunar and Mars CEV 14.710.2
160 ( 0 ft )
140 (3500 ft)
21
26.5 0-14.9
Lunar and Mars Landers 10.28.0
140 (3500 ft) 
132 (5000 ft)
26.5
32 0-14.9
Lunar and Mars Surface Suits 4.36.0
222
310
100
100 3.5-8.0 
2
1.13 from 8.0 psia 
Landers to 4.3 
psia suit; 
1.07 from 7.6 psia 
Surface 
Habitats to 4.3 
psia suit
Lunar and Mars Surface Habitats 8.07.6
132 (5000 ft)
126 (6500 ft)
32
32 0-14.9
Mars Transit 14.710.2
160 ( 0 ft )
140 (3500 ft)
21
26.5 0-14.9
Mercury/Gemini/ApolloSkylab
Early Apollo Design
Shuttle EVA Preparation
Shuttle/Mir/ISS
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NASA Spacecraft Atmosphere Design Space
Region of
Unimpaired
PerformanceHypoxic
Region
Region of
Oxygen 
Toxicity
Derived from NASA STD-3000, Vol. I, Rev. B
8NASA Spacecraft Atmosphere Design Space 
From NASA-CR-2005-213689, Lange, et al.
Shuttle/ISS
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P(DCS)
0
0.0005
0.005
0.02
0.05
0.089
0.15
0.20
0.25
0.30
R
0.74
0.97
1.13
1.27
1.40
1.50
1.61
1.69
1.75
1.81
P(DCS) (see Table)
0.089
0
0.02
0.0005
0.30 Curves of constant DCS 
probability for a 41.4 kPa (6 
psia) space suit with a 60 
minute prebreathe. Calculation 
based on 4 hr EVA with 
exercise.  Resultant design 
space is shown shaded (green).
Current EAWG Recommended Constellation Atmospheres
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10
Background and Rationale for Atmosphere Recommendations
 Hypoxia:
 Aviation experience:  
 Commercial airline cabins up to 8000 ft without supplemental oxygen
 Military operations up to 10000 ft without supplemental oxygen
 Space experience:  
 All previous NASA programs were at 6000 ft or lower
 ISS excursions per Flight Rule with time duration limits
 US Air Force research:  
 Recently reported Brooks data show 8000 feet has minimal cognitive effect
 Decompression sickness:
 Space experience:  no reported in-flight DCS for Shuttle/ISS (Apollo ascent report by one 
crewmember).
 Much zero-g experience, but little in hypogravity environments
 NASA ground testing shows higher DCS incidence than zero-g
 Expect that lunar gravity ambulation will have significantly higher risk than zero-g
 Flammability:
 Space experience:  Apollo, Mir, Shuttle fire events
 Apollo-1:  catastrophic outcome
 Mir-22 and Shuttle:  non-catastrophic (materials usage controls, larger vehicles, much 
lower oxygen concentrations)
 Flammability threshold testing will give better materials characterization versus current pass/fail 
testing (NASA STD-6001 standard test).  Characterization of pyrolysis products is also needed.
11
Physiological Effects of Hypobaric Exposure
♦ Ascent causes a decrease in PaO2 sensed by the 
peripheral and central chemoreceptors, leading to 
increased rate of pulmonary ventilation (VE).
♦ Hyperventilation in response to hypoxia increases PAO2
and subsequently decreases alveolar carbon dioxide 
(PACO2) and leads to a transient alkalosis. 
♦ There is also a hypoxia-induced diuresis as the kidney 
attempts to return to a balanced pH with the excretion of 
bicarbonate.
12
13
Other Physiological Effects
♦ Transient ↑in 
Pulmonary artery 
pressure
♦ ↑Hgb / HCT, 
viscosity
♦ Shift of O2 / HgB
curve to left
♦ cellular changes
♦ Increased 
catecholamines
⎯ ↑HR
⎯ ↑CO
⎯ ↑Venous Tone
♦ ↓Plasma Volume
♦ ↓Stroke Volume
14
The Spectrum Of Hypoxia
♦ There is some confusion and overlap among the high altitude 
syndromes.
♦ A sudden ascent to high altitude can result in a rapid death 
from Acute Hypoxia while a more gradual ascent to the same 
altitude can result in AMS or no symptoms at all.
♦ Symptoms of AMS generally take a longer period of time to 
develop (hrs-days) and there is great variability among the 
population of those who are susceptible.
♦ Severe and prolonged forms of AMS may lead to High Altitude 
Pulmonary Edema (HAPE) and High Altitude Cerebral Edema 
(HACE) and death.
15
The Lake Louise AMS Scoring System
♦ Based on this committee’s recommendations:
⎯ A diagnosis of AMS is based on a recent gain in altitude, at least 
several hours (>2) at the new altitude, and the presence of headache 
and at least one of the following symptoms: gastrointestinal upset, 
fatigue or weakness, dizziness or lightheadedness and difficulty
sleeping. 
♦ A score of three points or greater on the AMS Self-
Report questionnaire alone or in combination with the 
clinical assessment score is diagnostic of AMS.
16
1. Headache 0 No headache
1 Mild Headache
2 Moderate Headache
3 Severe Headache, incapacitating
2. Gastrointestinal 
Symptoms 0 No gastrointestinal symptoms
1 Poor appetite or nausea
2 Moderate nausea or vomiting
3 Severe nausea & vomiting, incapacitating
Fatigue and/or Weakness 0 Not tired or weak
1 Mild fatigue/weakness
2 Moderate fatigue/weakness
3 Severe fatigue/weaknes, incapacitating
Dizziness/lightheadedness 0 Not Dizzy
1 Mild dizziness
2 Moderate dizziness
3 Severe dizziness, incapacitating
Difficulty sleeping 0 Slept as well as usual
1 Did not sleep as well as usual
2 Woke many times, poor night's sleep
3 Could not sleep at all
•Each question asked 
and the sum is 
calculated as the AMS 
self report score
Self Report questionnaire
17
6. Change in Mental 
Status 0 No Change in Mental Status
1 Lethargy/lassitude
2 Disoriented/confused
3 Stupor/semiconsciousness
4 Coma
7. Ataxia (heel to toe 
walking) 0 No Ataxia
1 Maneuvers to maintain balance
2 Steps off line
3 Falls down
4 Can't stand
8. Peripheral Edema 0 No peripheral edema
1 Peripheral edema at one location
2 Peripheral edema at two or more locations
The interviewers ratings of 
three signs: 
Added to the self-report 
score (Roach 1993)
Clinical Assessment
This system helped to standardize the diagnosis of AMS.
18
The Great Debate
♦ Despite over a century of research there 
remains a vigorous debate on the etiology 
and pathophysiology of AMS.
19
Paul Bert  (1833-1886)
♦ A French Physiologist considered the founder of 
Aerospace Medicine.
♦ Demonstrated, that the symptoms of AMS could 
be prevented or relieved by oxygen breathing and 
so “Proved” that it was the decrease in partial 
pressure of oxygen  & subsequent hypoxia at high 
altitude, that caused AMS.
♦ This doctrine that hypoxia alone is the cause for 
AMS has held true for 150 years.
20
Loepkky, Roach, Tucker, and others
But over the last thirty years, a new group of 
researchers have begun to question the 
conventional wisdom that the symptoms of 
AMS are solely due to hypoxia.
21
“the diminution of barometric pressure acts upon the 
living beings only by lowering the oxygen tension in 
the air, in the breath, and in the blood which supplies 
their tissues…. The increase in barometric pressure 
acts only by increasing oxygen tension in the air and 
blood….”  Paul Bert, 1878.
♦ Consequently, maintaining sea level equivalent partial 
pressures of O2 at any and all altitudes we “assume” no signs 
and symptoms of AMS should be seen.
22
Solid circles connected by the curve are studies done where HH was induced by ascent to altitude on 
air, but are HH exposures without simulated μG.  The open boxes are exposures where μG
adaptation through simulation or actual exposure is present as part of the HH.  The two least stressful 
points along the curve at 6,000 and 7,000 feet are from Ge (2002) where he shows a slight increase 
in plasma EP concentration.  The third point at 8,000 feet from Ge (2002) is within the open box from 
Waligora (1982).
23
Variable Pressure with Supposedly Equivalent Normoxia
A B C
21% O2 @ 760mmHg 31% O2 @ 523 mmHg 49% O2 @ 349mmHg
Sea Level 10,000 ft 20,000 ft
PAO2 = 104 mmHg PAO2 = 103 mmHg PAO2 = 104 mmHg
PAO2 = 61 mmHgPAO2 = 61 mmHgPAO2 = 61 mmHg
20,000 ft10,000 ftSea Level
32.5% O2 @ 349mmHg21% O2 @ 523 mmHg14% O2 @ 760mmHg
CBA
Variable Pressure with Supposedly Equivalent Hypoxia
Equivalent normoxic air altitudes:  A= B = C
no AMS is expected?
Equivalent hypoxic altitudes:  A = B = C
all equal time-course and incidence of AMS symptoms?
24
Tucker, 1983
♦ Evaluate multiple hypotheses of cardiopulmonary 
changes associated with AMS.
Normoxic, PAO2 = 103 
mmHg
Hypoxic, PAO2<103 
mmHg
Normobaric, PB
= 760 mmHg
Altitude 1520
PAO2 = 77
No AMS symptoms
Altitude 1520 m
PAO2 = 47.1
Mean AMS Score: 3.2
Hypobaric 
PB<760 mmHg
Altitude 4570 m 
PB = 430 mmHg
PAO2 = 45
Mean AMS Score: 6.75
** Environmental Symptoms Questionnaire (ESQ)
25
Roach, 1996
♦ Document the effect of hypobaria on the 
pathophysiology of AMS. 
Normoxic, PAO2 = 
103 mmHg
Hypoxic, PAO2<103 
mmHg
Normobaric, PB
= 760 mmHg
Altitude 1520 m
PAO2 = 76
No AMS symptoms
Altitude 1520 m
PAO2 = 47.1
Mean AMS Score: 2.0
Hypobaric 
PB<760 mmHg
Altitude 4570 m
PAO2 = 74.5
Mean AMS score: 0.4
Altitude 4570 m 
PAO2 = 46
Mean AMS Score: 3.7
*Lake Louise scoring system
“we found that 
simulated altitude 
induces AMS to a 
greater extent than 
either normobaric
hypoxia or normoxic
hypobaria, although 
normobaric hypoxia 
induced some AMS.”
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The Pressure Effect!
♦ There are few other direct studies on the incidence of 
AMS in normal versus hypobaric hypoxia.
♦ Additional research has attempted to define the 
physiological differences that can be directly related to 
barometric pressure alone.
♦ Many of these have left us with more questions then 
answers.
27
Pathophysiology
♦ A variety of explanations have been 
proposed for AMS and the effect of 
barometric pressure.
28
Hypobaric Hypoxia versus Normobaric Hypoxia
♦ Decreased gas density 
relative to 1 ATA
♦ Decreased quantity of gas in 
solution relative to 1 ATA
♦ Increased insensible water 
loss relative to 1 ATA
♦ Transient N2 gradient out of 
tissues
♦ Potential for VGE
♦ Gas density at 1 ATA
♦ Gas in solution at 1 ATA
♦ Insensible water loss at 1 ATA
♦ Transient N2 gradient into 
tissues
♦ No potential for VGE
29
In the Past….
♦ NASA’s past habitats and vehicles rarely 
exposed the astronaut to hypobaric and 
hypoxic conditions.
♦ Staged decompression protocols taking many 
hours to days with very high O2 levels were 
used in the past.
♦ Likelihood of AMS almost nil.
30
Vision For Space Exploration (2004)
♦ Specifies the development of human 
missions to Earth’s moon, Mars and beyond.
♦ In order to accomplish this task NASA will be 
required to build an array of vehicles 
including interplanetary spacecraft, planetary 
landers, space suits, rovers and surface 
habitats.
31
♦ Due to the technical, financial and mission operational 
constraints, the most likely atmospheres of this constellation of 
habitats, vehicles, suits and rovers will likely be well below 
standard pressure (PB). 
♦ Future moon and mars missions with CEV, LSAM and lunar 
habitat amongst other issues will require efficient EVA egress 
with minimal prebreathe time while still avoiding DCS and 
venous gas emboli (VGE).
♦ This combination of hypobaria with a concomitant hypoxia 
simulates the conditions encountered by high altitude climbers.
32
SO….. 
Are we putting future astronauts at an 
increased risk for AMS and all it’s associated 
symptoms?
33
Incidence Of AMS
♦ The incidence of AMS as reported in the literature is highly 
variable.
♦ Most agree that some people may show mild AMS symptoms 
as low as 1,981-2,438m (6,500-8,000 ft).
♦ One report claims that as much as 25% of people may be 
affected with quick ascent to 1,891m, with 90% of symptoms 
resolving in 3 – 4 days.
♦ Houston C.S. claims that 25-30% of people ascending to 3,048m 
(10,000 ft) will experience some type of AMS, this figure will 
double at 4,200m and almost all people will show some signs of 
AMS by 5,486m (18,000 ft).
♦ Roach et al 1998 that a small percentage, 5% of people who 
develop AMS at 3,962m (13,000 ft) will go on to develop life 
threatening HAPE and/or HACE.
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♦ Based on extrapolation of current research it 
does not seem likely that one may 
experience severe AMS. 
♦ The bigger issue is likely Performance.
♦ The bigger issue is a mitigation plan.
What Happens If Future Astronauts Develop AMS?
35
Performance
♦ Will the performance of future astronauts be effected?
♦ Can we still maintain a quick egress for EVA while 
safely balancing engineering, mission control, DCS, 
and AMS with minimal prebreathe times?
♦ What minimum PAO2 can we maintain to satisfy all the 
above?
36
Performance
♦ There have been almost no direct studies on the effect 
of AMS on performance.
♦ Montgomery in 1989 stated that the incidence of AMS 
at 1,981m (6,500 ft) was approximately 12% and further 
stated that 50% of these subjects took medication for 
relief of symptoms.
♦ He did not go as far as to quantify a decrease in 
effective performance during this study.
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Treatment of AMS
♦ If it is determined that AMS is an acceptable 
risk for future space flight, a plan of 
treatment must be established.
♦ Mild AMS is treated by: 
• Halting ascent 
• Await acclimatization
• Acetazolamide (125-250 mg BID) 
• O2 therapy; .05-1.0 l/min mask or cannula:
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AMS Prevention
♦ The best predictor of AMS is history of prior episode
♦ Acetazolamide has proven effective for AMS prophylaxis 
♦ Roach et al. 1998 showed  “development of AMS was 
significantly and negatively correlated with SaO2%”…. 
“subjects with SaO2% above 84% appear immune to developing 
AMS at the altitudes tested.”
39
Actions of acetazolamide
40
Other Considerations
♦ Potential negative synergy between mild 
hypoxia and adaptation to mG.
♦ Does mG change the incidence of AMS? 
• redistribution of lung fluid
• increased interstitial edema
• altered incidence of HAPE?
41
Optimum HCT for O2 transport
42
Future AMS work
♦ Unique experiments duplicating the atmospheres and 
conditions for the proposed CEV, LSAM, Habitats and EVA 
suits.
♦ Determine who may be at risk for developing AMS and it’s 
effects on that individual.
♦ Current knowledge does not allow us to predict those that are 
at risk for AMS, the best predictor is previous episodes. 
♦ Do we select future astronauts based on criteria to reduce the 
risk?
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Thank You
